

Ferozsons Laboratories Limited
Unconsolidated Statement of Profit or Loss
For the year ended 30 June 2023

	Note	2023 Rupees	2022 Rupees
Revenue - net	25	9,893,390,922	7,806,414,315
Cost of sales	26	<u>(6,071,103,751)</u>	<u>(4,288,798,744)</u>
Gross profit		3,822,287,171	3,517,615,571
Administrative expenses	27	(611,974,082)	(492,093,958)
Selling and distribution expenses	28	(2,446,540,871)	(1,971,142,023)
Other expenses	29	(532,563,028)	(266,092,166)
Other income	30	<u>202,484,754</u>	<u>183,650,968</u>
Profit from operations		433,693,944	971,938,392
Finance cost	31	<u>(158,362,247)</u>	<u>(37,406,319)</u>
Profit before taxation		275,331,697	934,532,073
Taxation	32	<u>(86,289,226)</u>	<u>(420,383,200)</u>
Profit after taxation		<u>189,042,471</u>	<u>514,148,873</u>
			<i>Re-stated</i>
Earnings per share - basic and diluted	33	<u>4.35</u>	<u>11.83</u>

The annexed notes from 1 to 42 form an integral part of these unconsolidated financial statements.

KPMG


Chief Executive Officer

Chief Financial Officer

Director

Ferozsons Laboratories Limited
Consolidated Statement of Profit or Loss
For the year ended 30 June 2023

	Note	2023 Rupees	2022 Rupees
Revenue - net	27	11,457,221,348	9,329,917,808
Cost of sales	28	<u>(7,196,032,930)</u>	<u>(5,346,666,882)</u>
Gross profit		4,261,188,418	3,983,250,926
Administrative expenses	29	(655,276,943)	(551,124,994)
Selling and distribution expenses	30	(2,605,330,646)	(2,133,242,551)
Other expenses	31	(560,199,693)	(299,043,460)
Other income	32	<u>278,408,150</u>	<u>333,361,268</u>
Profit from operations		718,789,286	1,333,201,189
Finance cost	33	<u>(304,117,871)</u>	<u>(96,278,493)</u>
Profit before taxation		414,671,415	1,236,922,696
Taxation	34	<u>(118,429,591)</u>	<u>(447,133,674)</u>
Profit after taxation		296,241,824	789,789,022
<i>Attributable to:</i>			
Owners of the Group		271,267,541	734,430,755
Non-controlling interests		<u>24,974,283</u>	<u>55,358,267</u>
Profit after taxation		296,241,824	789,789,022
Earnings per share - basic and diluted	35	<u>6.24</u>	<u>Re-stated 16.90</u>

The annexed notes from 1 to 47 form an integral part of these consolidated financial statements. 

Chief Executive Officer

Chief Financial Officer

Director